The ARPC1B Knockout A-549 Polyclonal Cells product is a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma line. It features targeted disruption of the ARPC1B gene, eliminating expression of the Arp2/3 complex subunit. As a polyclonal pool, this heterogeneous knockout population enables robust phenotypic analysis without single-cell cloning. The CRISPR/Cas9-mediated gene disruption provides a stable loss-of-function system for investigating ARPC1B-dependent processes in cancer-relevant contexts.
The host cell line, A-549, is a human epithelial cell line derived from a lung adenocarcinoma of a 58-year-old male. It is widely used as a model for non-small cell lung cancer (NSCLC) in cancer biology, drug development, and metastasis studies. Its epithelial origin and stable growth make it ideal for investigating cell motility, cytoskeletal dynamics, and signal transduction. The A-549 background provides a clinically relevant platform to probe the role of ARPC1B in oncogenic processes and to test therapies targeting actin regulation.
ARPC1B encodes the p41 subunit of the Arp2/3 complex, which nucleates branched actin filaments. The complex is activated by factors like WASP, WAVE1, and cortactin, downstream of Rho GTPases Rac1 and Cdc42, PI3K, and integrin signaling. ARPC1B integrates these inputs to promote lamellipodia formation, endocytic trafficking, and focal adhesion assembly, driving cell migration. Disruption of ARPC1B impairs Arp2/3 function, blocking actin polymerization and processes such as phagocytosis and immune synapse formation. The knockout disrupts interactions with complex members ARP2, ARP3, other ARPC subunits, and regulators like WAVE complex and cortactin.
In A-549 lung adenocarcinoma cells, ARPC1B knockout dissects the link between actin dynamics and cancer progression. ARPC1B facilitates migration and invasion??key metastatic traits??so its loss is expected to attenuate lamellipodia-driven motility. This model is especially relevant for studying Arp2/3-mediated actin branching in NSCLC dissemination. Although ARPC1B mutations cause immunodeficiency 71 and platelet disorders, here the focus is tumor cell-autonomous roles. Researchers can assess how Rho GTPase and WAVE signaling control metastatic behavior in lung adenocarcinoma via actin regulation.
This polyclonal knockout product supports actin visualization via immunofluorescence, wound healing and transwell migration/invasion assays to measure motility, and phagocytosis assays for endocytic function. It suits drug screens targeting actin dynamics or Rho GTPase pathways, plus studies of integrin and growth factor signaling. Proliferation and drug sensitivity assays may reveal ARPC1B-dependent viability and therapeutic responses. The polyclonal nature captures heterogeneous knockout effects, reflecting physiological variability. For technical inquiries or custom solutions, contact Ascent Research.
